PLMA_1170x120_7-2-21

Chirag Patel and Chintu Pate

Amneal launches generic Butrans following ANDA approval by FDA

Amneal launches generic Butrans following ANDA approval by FDA

BRIDGEWATER, N.J. — Amneal Pharmaceuticals announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Butrans (buprenorphine) Transdermal System, 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr and 20 mcg/hr. In addition, Amneal was granted the Competitive Generic Therapy (CGT) designation